Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease

被引:6
|
作者
Boada, Merce [1 ]
Martinez-Lage, Pablo [2 ]
Serrano-Castro, Pedro [3 ]
Costa, Montserrat [4 ]
Paez, Antonio [4 ]
机构
[1] Univ Int Catalunya, Ace Alzheimer Ctr Barcelona, Barcelona, Spain
[2] Fdn CITA Alzheimer Fundazioa, Ctr Invest & Clin Memoria, San Sebastian, Spain
[3] Hosp Reg Univ Malaga, Inst Invest Biomed Malaga, Malaga, Spain
[4] Grifols Biosci Res Grp, Barcelona, Spain
关键词
Alzheimer's disease; albumin; amyloid-beta; therapeutic plasma exchange; plasma exchange; neurodegenerative disease; AMYLOID-BETA-PEPTIDE; HUMAN SERUM-ALBUMIN; CEREBROSPINAL-FLUID; WRITING COMMITTEE; AMERICAN SOCIETY; ASSOCIATION; BINDING; GUIDELINES; NEUROINFLAMMATION; INFLAMMASOME;
D O I
10.1080/14737175.2021.1960823
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most common cause of dementia. It has a complex pathophysiology that is not yet completely understood, where multiple central, systemic, and environmental factors play a key role in disease progression. Understanding the multifactorial nature of AD is paramount to formulate new therapies. Areas covered The authors reviewed the role of the amyloid-beta-binding, antioxidant, and immunomodulatory properties of albumin in AD and the use of therapeutic plasma exchange (PE) in neurology. The results from the Alzheimer Management By Albumin Replacement (AMBAR) trial that combined the use of PE with albumin replacement in patients with mild-to-moderate AD, are also analyzed. Expert opinion Findings from the AMBAR study provide encouraging results in the treatment of AD with PE and albumin replacement, especially in patients at the moderate stage of the disease, who showed less cognitive decline from baseline compared with placebo in most of the variables analyzed. Further research is warranted to ascertain the possible mechanisms of action underlying these results. Different cohorts of patients that may also benefit from this treatment, such as those with mild cognitive impairment or other types of dementia, could also be the target of additional studies.
引用
收藏
页码:843 / 849
页数:7
相关论文
共 50 条
  • [1] Memantine nanoemulsion: a new approach to treat Alzheimer's disease
    Kaur, Atinderpal
    Nigam, Kuldeep
    Srivastava, Sukriti
    Tyagi, Amit
    Dang, Shweta
    JOURNAL OF MICROENCAPSULATION, 2020, 37 (05) : 355 - 365
  • [2] Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?
    Menendez-Gonzalez, Manuel
    Gasparovic, Charles
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [3] Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management
    Costa, Montserrat
    Paez, Antonio
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (03)
  • [4] Alzheimer's Disease: Inflammation as a new therapeutic approach
    不详
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2013, 28 (02): : 198 - 199
  • [5] New Possibilities in the Therapeutic Approach to Alzheimer's Disease
    Doroszkiewicz, Julia
    Mroczko, Barbara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [6] Plasma Exchange in Alzheimer?s Disease
    Rohrer, Lucas
    Yunce, Muharrem
    Montine, Thomas J.
    Shan, Hua
    TRANSFUSION MEDICINE REVIEWS, 2023, 37 (01) : 10 - 15
  • [7] Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study
    Boada, Merce
    Kiprov, Dobri
    Anaya, Fernando
    Lopez, Oscar L.
    Nunez, Laura
    Olazaran, Javier
    Lima, Jose
    Grifols, Carlota
    Barcelo, Miquel
    Rohe, Regina
    Prieto-Fernandez, Cristina
    Szczepiorkowski, Zbigniew M.
    Paez, Antonio
    JOURNAL OF CLINICAL APHERESIS, 2023, 38 (01) : 45 - 54
  • [8] The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review
    Cantero-Fortiz, Yahveth
    Boada, Merce
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [9] Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?
    Imbimbo, Bruno P.
    Ippati, Stefania
    Ceravolo, Ferdinando
    Watling, Mark
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2020, 6 (01) : 1 - 11
  • [10] AMYLOID-TARGETED THERAPEUTICS IN ALZHEIMER'S DISEASE: USE OF HUMAN ALBUMIN IN PLASMA EXCHANGE AS A NOVEL APPROACH FOR Aβ MOBILIZATION
    Boada, Merce
    Ortiz, Pilar
    Anaya, Fernando
    Hernandez, Isabel
    Munoz, Joan
    Nunez, Laura
    Olazaran, Javier
    Roca, Isabel
    Cuberas, Gemma
    Tarraga, Lluis
    Buendia, Mar
    Pla, Ramon P.
    Ferrer, Isidre
    Paez, Antonio
    DRUG NEWS & PERSPECTIVES, 2009, 22 (06) : 325 - 339